<div>
                                <figure class="article-image__container">
                                    
                                    
                                    
                                    <img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/PT-19-12-2025-9361151-RYBREVANT-FASPRO-Manufacturing-Image1-430x241.jpeg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/PT-19-12-2025-9361151-RYBREVANT-FASPRO-Manufacturing-Image1-430x241.jpeg"/>
                                    
                                    <figcaption>The study demonstrated that Rybrevant Faspro has met co-primary pharmacokinetic endpoints. Credit: Johnson &amp; Johnson / PRNewswire.</figcaption>
                                </figure>
                            </div>
                                             
     
<p>Johnson &amp; Johnson (J&amp;J) has received the US Food and Drug Administration (FDA) approval for Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), a subcutaneously (SC) administered therapy to treat patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).</p>



<p>The approval covers all existing indications for Rybrevant.</p><div>
<div id="div-gpt-ad-6065588-4"></div>
  
</div><div><div>
                   <div><h3>Go deeper with GlobalData</h3><ul><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - AMC-303 in Squamous Non-Small Cell Lung Carcinoma </h4></div> </li><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - COM-701 in Non-Small Cell Lung Cancer </h4></div> </li></ul> <div>
                    <h5>
                                                Go deeper with GlobalData
                                            </h5>
                    <p>
                        The gold standard of business intelligence.
                    </p>
                    <p>
                            Find out more
                            
                                
                            
                        
                    </p>
                </div>
                </div></div><section><figure><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></figure><h4> Discover B2B Marketing That Performs </h4><p>
						Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
					</p><p>
							Find out more </p></section></div>



<p>The SC formulation reduces administration time from several hours to five minutes, compared to intravenous (IV) delivery, offering increased patient convenience and decreasing healthcare resource use.</p><div id="slot-one"></div><div id="Sgpollsputhere"></div>



<p>Rybrevant’s approval is supported by results from the Phase III PALOMA-3 study, which demonstrated that the therapy met both co-primary pharmacokinetic endpoints.</p>



<p>These findings were initially presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and published in the Journal of Clinical Oncology.</p>



<p>Further PALOMA-3 data showed that the SC arm, in combination with Lazcluze (lazertinib), had longer overall survival (OS), longer duration of response, and improved progression-free survival compared to the IV arm. At 12 months, 65% of patients in the SC group were alive, against 51% in the IV group.</p><div> 
                         <div>


            <div>

                <img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/>
            </div>


            <div>

                <span class="gdm-company-profile-unit__form-excerpt">GlobalData Strategic Intelligence</span>
 <div id="gdm-form-wrapper">



                    <h1>
                        US Tariffs are shifting - will you react or anticipate?
                    </h1>
                    <p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
                    <span class="gdm-company-profile-unit__text">By GlobalData</span>
                
          </div>
          </div>  
           </div> Learn more about Strategic Intelligence</div>



<p>J&amp;J’s innovative medicine solid tumour president Biljana Naumovic said: “The approval of Rybrevant Faspro is a pivotal step forward, as EGFR+ NSCLC patients have previously faced limited treatment options.</p>



<p>“Now, patients are gaining greater access to this transformative treatment, as well as the tools needed to proactively manage common dermatological effects.”</p><div id="slot-two"></div>



<p>The safety profile of Rybrevant Faspro in combination with Lazcluze was found to be largely consistent with IV administration.</p>



<p>Common adverse reactions (≥ 20%) of the combination included musculoskeletal pain, haemorrhage, decreased appetite, and peripheral neuropathy.</p>



<p>Last month, J&amp;J signed a definitive agreement to acquire Halda Therapeutics (Halda) in a $3.05bn cash deal.</p>
<div id="slot-three"></div><p></p>



<div>
    
</div>



                   
               <div>
                 <h2>Pharmaceutical Technology Excellence Awards - Nominations Closed</h2>
                 <p>Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.
<br/>
<br/>
<strong>Excellence in Action</strong>
<br/>Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.</p>
Discover the Impact

             </div>

<p>Johnson & Johnson (J&J) has received US FDA approval for Rybrevant Faspro, a subcutaneously administered therapy for treating patients with EGFR-mutated non-small cell lung cancer (NSCLC). The approval is based on the Phase III PALOMA-3 study, which showed improved overall survival and progression-free survival compared to intravenous delivery. The SC formulation reduces administration time to five minutes, enhancing patient convenience. The safety profile is consistent with IV administration. This approval provides greater access to treatment for EGFR+ NSCLC patients.</p>

J&J receives FDA approval for lung cancer therapy